Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd share price slipped 0.04% to Rs 27.0 after the company's net profit tumbled by 43.07% to Rs 7.64 crore, while revenue from operations reduced 15.11% to Rs 57.12 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, gaining 4.31%. It has marginally improved by 0.98% over last one week and advanced by 11.49% in last one month while the market capitalization of Mangalam Drugs and Organics Ltd has inched up 0.45% and 9.99% in the same period respectively. Profit before tax (PBT) of Mangalam Drugs and Organics Ltd stood at Rs 6.75 crore in Q2 FY26, plunging by 48.08% year-on-year, and crashing by 49.13% quarter-on-quarter. EBITDA came in at Rs 1 crore, nosediving by 116.84% YoY and tanking 114.01% sequentially. Total expenses plunged by 22.26% to Rs 60.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 33.59 crore, marginally falling by 5.41% YoY, while employee benefits expense was at Rs 8.91 crore, ticking higher by 4.95% YoY. For the TTM ended FY26, revenue from operations declined by 13.55% to Rs 317.58 crore, while net profit tanked by 174.09% to Rs 6.72 crore, compared to previous TTM. EBITDA jumped by 1826% to Rs 34.01 crore, and PBT collapsed by 143.27% to Rs 4.79 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 42.59 crore in FY26, as against Rs 3.91 crore in FY25. Mangalam Drugs and Organics Ltd nosedived by 65.03% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.04% during the same period.

Net loss of Mangalam Drugs and Organics reported to Rs 13.42 crore in the quarter ended March 2026 as against net profit of Rs 0.06 crore during the previous quarter ended March 2025. Sales declined 7.54% to Rs 67.29 crore in the quarter ended March 2026 as against Rs 72.78 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 44.40 crore in the year ended March 2026 as against net profit of Rs 6.72 crore during the previous year ended March 2025. Sales declined 26.91% to Rs 232.13 crore in the year ended March 2026 as against Rs 317.58 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales67.2972.78 -8 232.13317.58 -27 OPM %-8.3513.60 --6.4211.07 - PBDT-8.616.34 PL -30.3521.39 PL PBT-13.271.63 PL -48.574.79 PL NP-13.420.06 PL -44.406.72 PL Powered by Capital Market - Live

Mangalam Drugs and Organics will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Mangalam Drugs and Organics will hold a meeting of the Board of Directors of the Company on 26 March 2026.Powered by Capital Market - Live

Mangalam Drugs and Organics will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live

Net loss of Mangalam Drugs and Organics reported to Rs 9.84 crore in the quarter ended December 2025 as against net profit of Rs 1.29 crore during the previous quarter ended December 2024. Sales declined 34.07% to Rs 58.38 crore in the quarter ended December 2025 as against Rs 88.55 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales58.3888.55 -34 OPM %-2.459.90 - PBDT-5.375.42 PL PBT-9.841.37 PL NP-9.841.29 PL Powered by Capital Market - Live

Mangalam Drugs and Organics will hold a meeting of the Board of Directors of the Company on 15 January 2026.Powered by Capital Market - Live

Net loss of Mangalam Drugs and Organics reported to Rs 7.35 crore in the quarter ended September 2025 as against net profit of Rs 2.69 crore during the previous quarter ended September 2024. Sales declined 38.23% to Rs 49.26 crore in the quarter ended September 2025 as against Rs 79.75 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales49.2679.75 -38 OPM %-5.7710.91 - PBDT-7.845.17 PL PBT-12.471.20 PL NP-7.352.69 PL Powered by Capital Market - Live

Billionbrains Garage Ventures Ltd, Physicswallah Ltd, Diffusion Engineers Ltd and Anand Rathi Share & Stock Brokers Ltd are among the other losers in the BSE's 'B' group today, 19 November 2025.Mangalam Drugs and Organics Ltd crashed 11.65% to Rs 54.02 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 9247 shares were traded on the counter so far as against the average daily volumes of 2211 shares in the past one month.Billionbrains Garage Ventures Ltd lost 10.00% to Rs 169.94. The stock was the second biggest loser in 'B' group.On the BSE, 245.95 lakh shares were traded on the counter so far as against the average daily volumes of 651.34 lakh shares in the past one month.Physicswallah Ltd tumbled 9.12% to Rs 141.05. The stock was the third biggest loser in 'B' group.On the BSE, 122.91 lakh shares were traded on the counter so far as against the average daily volumes of 297.09 lakh shares in the past one month.Diffusion Engineers Ltd shed 8.98% to Rs 315.6. The stock was the fourth biggest loser in 'B' group.On the BSE, 9609 shares were traded on the counter so far as against the average daily volumes of 3805 shares in the past one month.Anand Rathi Share & Stock Brokers Ltd pared 7.98% to Rs 711.35. The stock was the fifth biggest loser in 'B' group.On the BSE, 2.22 lakh shares were traded on the counter so far as against the average daily volumes of 1.43 lakh shares in the past one month.Powered by Capital Market - Live

Mangalam Drugs and Organics has postponed the meeting of the Board of Directors which was scheduled to be held on 13 November 2025. The meeting will now be held on 20 November 2025.Powered by Capital Market - Live